Overview

Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer

Status:
Completed
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance atezolizumab in women with advanced ovarian cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Duke University
Collaborators:
Genentech, Inc.
Johns Hopkins University
Treatments:
Atezolizumab
Bevacizumab
Carboplatin
Paclitaxel